Summit Therapeutics Inc. (Nasdaq: SMMT) reported on July 22, 2026, that an updated analysis of the global Phase III HARMONi trial produced an overall survival hazard ratio of 0.76 for ivonescimab plus platinum-doublet chemotherapy versus placebo plus chemotherapy, both in the full intention-to-treat population and the Western patient subgroup. The company has provided the June 2026 analysis to the United States Food and Drug Administration, which is reviewing an ivonescimab Biologics License Application with a November 14, 2026, target decision date.
The update strengthens the direction and geographic consistency of the survival signal as follow-up among Western patients becomes more mature. It does not, however, amount to a newly declared prespecified statistical success. Summit Therapeutics has not yet released the updated median overall survival figures, confidence intervals, event maturity or p value from the June analysis, reserving those details for a future medical meeting.
That distinction is central to interpreting the announcement. Ivonescimab remains investigational in Summit Therapeutics’ licensed territories, including the United States and Europe, although it has received marketing authorisation in China. The latest HARMONi analysis potentially improves the evidence supporting the United States application, but the regulatory question remains whether the total benefit-risk package is persuasive despite the original overall survival analysis narrowly missing statistical significance.
Why does the June 2026 HARMONi survival cut matter without settling the statistical debate?
HARMONi enrolled 438 patients, with 219 assigned to ivonescimab plus chemotherapy and 219 receiving placebo plus chemotherapy. Participants had EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer that had progressed following treatment with a third-generation EGFR tyrosine kinase inhibitor.
At the prespecified primary overall survival analysis in April 2025, ivonescimab plus chemotherapy produced a hazard ratio of 0.79 compared with chemotherapy alone. Median overall survival was 16.8 months in the ivonescimab group and 14.0 months in the control group. The 95% confidence interval ranged from 0.62 to 1.01, while the p value of 0.057 fell just outside the conventional threshold for statistical significance.
A September 2025 analysis incorporating longer follow-up among Western patients produced a global hazard ratio of 0.78, with a 95% confidence interval of 0.62 to 0.98 and a nominal p value of 0.0332. Median overall survival remained unchanged between the two analyses. The use of a nominal p value matters because an exploratory or later analysis cannot automatically be interpreted in the same way as the trial’s prespecified primary test.
The June 2026 data cut moves the global hazard ratio to 0.76. This is directionally better than the April and September estimates, but the magnitude of the change is modest. The real importance is that the trend has not weakened as follow-up among Western participants has matured.
The remaining disclosure gap is substantial. Without the new confidence interval, median survival, event count and statistical methodology, it is not yet possible to judge the precision of the 0.76 estimate or determine how regulators will classify the additional analysis. The update is therefore meaningful regulatory evidence, but not a substitute for the complete dataset.
How does longer Western follow-up change confidence in ivonescimab’s geographic consistency?
The Western subgroup contained 165 patients, including 83 in the ivonescimab arm and 82 in the control arm. Its overall survival hazard ratio changed from 0.98 in April 2025 to 0.84 in September and 0.76 in the June 2026 analysis.
That progression coincided with median Western follow-up increasing from 9.2 months to 13.7 months and then 23.2 months. At the original analysis, the Western follow-up period was shorter than the observed median overall survival, leaving the subgroup immature and vulnerable to unstable estimates. Summit Therapeutics said most Western patients had either discontinued treatment or completed two years of therapy by the latest cutoff.
The movement from a hazard ratio close to 1.00 toward the global estimate addresses one of the questions created by the original results. A regulator reviewing a multiregional trial needs confidence that the treatment effect is not being driven entirely by one geography, particularly when the drug’s earlier development and commercial experience were concentrated in China.
The Asian dataset, however, remained locked at the previous cutoff, with median follow-up of 32.7 months. The new global hazard ratio therefore combines additional Western follow-up with an unchanged Asian dataset. This is useful for assessing whether the Western estimate converges with the more mature Asian result, but it is not a completely new global follow-up analysis in which every region advanced to the same date.
The Western subgroup was also smaller than the full trial population and was not a separate independently powered study. Its improved hazard ratio supports consistency, but it should not be treated as standalone proof of efficacy. A hazard ratio of 0.76 indicates an estimated 24% reduction in the instantaneous risk of death over the observation period, subject to the model’s assumptions. It does not mean that patients necessarily lived 24% longer.
What does the complete HARMONi efficacy package show beyond the updated survival ratio?
The strongest formally positive component of HARMONi remains progression-free survival, one of the trial’s two primary endpoints. Ivonescimab plus chemotherapy reduced the estimated risk of progression or death by 48%, producing a hazard ratio of 0.52 with a 95% confidence interval of 0.41 to 0.66 and a p value below 0.00001.
Median progression-free survival was 6.8 months with ivonescimab and chemotherapy compared with 4.4 months for chemotherapy alone. A longer-term analysis produced a hazard ratio of 0.57, with treatment effects reported as directionally consistent across Asian and Western populations and across patients with PD-L1-positive and PD-L1-negative tumours.
The observed objective response rate was 45% in the ivonescimab group and 34% in the control group. Median duration of response was 7.6 months and 4.2 months, respectively. These measures reinforce the progression-free survival result by suggesting greater tumour activity and more durable disease control.
The trial design adds weight to those findings. HARMONi was randomised, double-blind and placebo-controlled, and progression-free survival was assessed by a blinded independent central review committee. Summit Therapeutics has also said that separate alpha levels were assigned to progression-free and overall survival, with alpha recycled to the survival analysis after the progression-free survival endpoint succeeded.
However, a 2.4-month difference in median progression-free survival must be assessed alongside treatment burden, toxicity and the evolving availability of competing regimens. Overall survival remains especially important in this setting because subsequent treatments can influence outcomes and because longer life, rather than delayed radiographic progression alone, carries the greatest clinical weight.
Can ivonescimab’s safety profile support a favorable benefit-risk assessment after EGFR therapy?
Ivonescimab combines PD-1 blockade with inhibition of vascular endothelial growth factor in a single tetravalent bispecific antibody. The design is intended to concentrate cooperative binding within the tumour microenvironment, potentially delivering immunotherapy and anti-angiogenic activity without simply administering two separate antibodies.
In the earlier detailed HARMONi analysis, 50.0% of patients receiving ivonescimab plus chemotherapy experienced Grade 3 or higher treatment-related adverse events, compared with 42.2% in the chemotherapy control group. Treatment-related adverse events led to discontinuation in 7.3% and 5.0% of patients, respectively.
Treatment-related deaths were reported in 1.8% of the ivonescimab group and 2.3% of the control group. Grade 3 or higher haemorrhage events occurred in 0.9% of patients receiving ivonescimab plus chemotherapy. That bleeding figure is particularly relevant for a therapy involving VEGF inhibition, although the low incidence in HARMONi will need to be considered within the broader safety database.
Summit Therapeutics said the June 2026 analysis revealed no additional safety signals and remained consistent with earlier Phase III data. That is reassuring after longer exposure, but the company did not disclose updated adverse-event tables, cumulative event rates or treatment discontinuation details with this announcement.
The eventual benefit-risk judgment will therefore depend on the complete safety dataset, including immune-related toxicity, hypertension, bleeding, proteinuria and other events associated with PD-1 or VEGF pathway inhibition. Clinicians will also need to consider whether any additional toxicity is justified by the magnitude and durability of the survival advantage.
How does HARMONi compare with a treatment landscape that has moved beyond chemotherapy alone?
The HARMONi comparator was platinum-based chemotherapy without another targeted antibody. That design clearly measures the contribution of ivonescimab, but the United States treatment landscape has changed since the study began.
The United States Food and Drug Administration approved amivantamab with carboplatin and pemetrexed in September 2024 for eligible patients with locally advanced or metastatic non-small cell lung cancer carrying EGFR exon 19 deletions or exon 21 L858R mutations whose disease progressed on or after an EGFR tyrosine kinase inhibitor.
In the MARIPOSA-2 trial supporting that approval, amivantamab plus chemotherapy achieved median progression-free survival of 6.3 months compared with 4.2 months for chemotherapy, with a hazard ratio of 0.48. Its overall survival hazard ratio at the second prespecified interim analysis was 0.73, although the difference had not reached statistical significance at that point.
Those figures provide treatment-landscape context, not a head-to-head comparison. Differences in trial populations, follow-up, subsequent treatments and statistical plans prevent a reliable conclusion that one regimen is more effective or safer than the other.
Datopotamab deruxtecan is also available under accelerated approval for patients with EGFR-mutated disease who have already received EGFR-directed therapy and platinum chemotherapy, adding another later-line option. This means ivonescimab would enter a market where treatment sequencing is increasingly complex rather than simply replacing chemotherapy in an empty therapeutic space.
If approved, ivonescimab’s commercial position will depend on its final label, survival evidence, toxicity profile, infusion requirements, pricing and reimbursement. Payers and oncology centres are likely to compare it with amivantamab-based treatment, while clinicians may examine whether the bispecific design offers a practical benefit for particular patient groups.
What will the FDA need to resolve before the November 14 ivonescimab decision?
The FDA accepted Summit Therapeutics’ Biologics License Application for filing in January 2026 and assigned a November 14 target action date. Filing acceptance confirms that the application was sufficiently complete for review, but it does not predict approval or validate the company’s interpretation of the evidence.
Summit Therapeutics previously disclosed that the FDA had indicated a statistically significant overall survival benefit would be needed to support marketing authorisation in this setting. The original HARMONi survival analysis did not achieve that result, making the agency’s treatment of the later analyses one of the most consequential questions surrounding the application.
The June hazard ratio of 0.76 may strengthen the totality of evidence, particularly because the same estimate was observed in the full population and the Western subgroup. Yet regulators will examine whether the analysis was prespecified, how missing data and subsequent therapies were handled, whether proportional hazards assumptions were met and whether the regional results are robust across sensitivity analyses.
Evidence from China provides additional biological and clinical context. In Akeso Inc.’s HARMONi-A study, ivonescimab plus chemotherapy achieved a final overall survival hazard ratio of 0.74, with median survival of 16.8 months versus 14.1 months and a p value of 0.019. Ivonescimab was approved in China for this post-EGFR treatment setting in May 2024 and subsequently entered the country’s reimbursement system.
HARMONi-A supports the consistency of the mechanism and treatment effect, but a China-only study cannot replace the multiregional evidence required for Western approval. The FDA’s decision will rest on the submitted HARMONi package, manufacturing and quality information, and the agency’s independent assessment of whether the benefit outweighs the risks for the proposed population.
Why does the HARMONi update improve sentiment without removing Summit Therapeutics’ execution risk?
Summit Therapeutics shares were quoted around $14.63 during July 22 trading, approximately 8.3% above the previous close. The company’s market capitalisation was around $11.35 billion, while its 52-week trading range extended from $12.55 to $30.98.
The positive session coincided with the survival update, although a single trading move cannot establish causation. Investor sentiment is likely to view the 0.76 hazard ratio as a regulatory de-risking signal, particularly after concerns about the original survival miss and the initially weaker Western estimate.
The shares nevertheless remain more than 50% below their 52-week high. That gap reflects the unusually concentrated nature of Summit Therapeutics’ valuation, which depends heavily on ivonescimab, the FDA review and the company’s ability to fund an expanding Phase III programme.
Summit Therapeutics reported $598.7 million in cash, cash equivalents and short-term investments at March 31, 2026, alongside a first-quarter net loss of $189.4 million. Non-GAAP research and development spending reached $108.2 million as the company expanded ivonescimab trials. A proposed $500 million public offering was withdrawn in June because of market conditions, leaving funding strategy relevant as development and potential commercial preparation accelerate.
The company is due to report second-quarter financial results on July 23, which should provide a fresher view of expenditure, liquidity and operational priorities. Strong clinical data can improve financing flexibility, but an approval-stage oncology programme with several global Phase III trials remains expensive.
Which clinical details will determine whether the new survival signal holds up?
The next medical presentation should disclose the updated median overall survival results, confidence intervals, p value, number of deaths, event maturity and outcomes by geography. Subsequent-treatment patterns will also matter because access to later therapies can influence overall survival and may differ substantially between Asia, North America and Europe.
Beyond the current application, HARMONi-3 is comparing ivonescimab plus chemotherapy directly with pembrolizumab plus chemotherapy in first-line metastatic non-small cell lung cancer. HARMONi-7 is testing ivonescimab monotherapy against pembrolizumab in patients whose tumours have high PD-L1 expression. Those studies will provide more direct evidence of whether ivonescimab can compete with established immunotherapy standards rather than chemotherapy alone.
For the immediate regulatory case, however, the June HARMONi analysis reduces the geographic inconsistency that complicated the original readout. It does not erase the missed prespecified survival test or the absence of detailed updated statistics. The decisive test is now whether the complete data package persuades the FDA that a persistent 0.76 survival hazard ratio, supported by positive progression-free survival and manageable safety, is sufficiently reliable and clinically meaningful for United States approval.
